Nov 2 (Reuters) - Teva Pharmaceuticals said on Monday it was discontinuing its mid-stage neurodegenerative disorder study due ...

Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if ...

Patients with geographic atrophy prefer treatments that preserve reading ability and distance vision despite potential risks of inflammation.

Geographic atrophy treatment has a new entrant: OliX Pharmaceuticals filed a US IND for OLX301A, a siRNA drug targeting MyD88, the retinal inflammation amplifier Syfovre and Izervay cannot silence.

Teva Pharmaceutical Industries is discontinuing a Phase 2 study for a multiple system atrophy treatment. The company said Monday the move follows a recommendation from an independent data monitoring ...

Chew Chor Meng leaves Mediacorp after 36 years, reflecting on his career and iconic roles in Singapore television. Read more at straitstimes.com.

Teva Pharma Industries Ltd ADRs (NYSE:TEVA) declined over 3% in premarket trading Monday after the company announced it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin (TEV-'286) following ...

A prospective neuroimaging study finds that atrophy patterns across frontotemporal dementia syndromes spatially align with ...

🚨 One Nation volunteer bashed with baseball bat in front of his family after confronting sign vandal The alleged attack is understood to have begun when a 14-year-old boy started damaging One Nation ...

Israeli drugmaker Teva Industries said it will discontinue its Phase II TOPAS-MSA study of emrusolmin (TEV-‘286) in adults with multiple system atrophy (MSA), after an interim analysis indicated a ...

Patient-specific CFD models show that lower false-lumen flow near the renal arteries emerges early after aortic dissection ...